India Glycols Limited has issued general guidance to shareholders on the apportionment of the cost of acquisition for equity shares in the company and its two newly formed resultants, Ennature Bio Pharma Limited and IGL Spirits Limited. This follows the implementation of a scheme of arrangement that demerged the Bio Pharma and Spirits & Biofuel undertakings, effective September 1, 2026.

The communication clarifies how existing shareholders should split their original investment base across the three listed entities for tax purposes under the Income Tax Act, 2025. The allotment ratios were set at one share of Ennature Bio Pharma for every three shares of India Glycols held, and one share of IGL Spirits for every one share of India Glycols held.

Cost of acquisition breakdown

Shareholders are advised to apportion their original cost of acquisition in India Glycols shares among the three entities based on specific percentages derived from the valuation of the demerged undertakings. This allocation is critical for calculating capital gains or losses upon future sale of these shares.

Regulatory context and shareholder advisory

The National Company Law Tribunal (NCLT), Allahabad Bench, sanctioned the scheme on July 17, 2026. The resulting companies allotted equity shares of ₹5 each to shareholders whose names appeared in the register of members as on the record date, September 2, 2026.

India Glycols emphasized that this guidance is for general information only and does not constitute professional tax advice. Shareholders are encouraged to consult independent tax advisors to determine the specific implications for their individual portfolios, noting that regulatory authorities may take a different view on the apportionment methodology.

India Glycols Limited has changed the mode of its scheduled interactions with analysts and institutional investors for October 7 and 8, 2026, from in-person to virtual. The update applies to both the non-deal meeting and the roadshow originally planned for Mumbai.

The company filed this intimation with BSE Limited and the National Stock Exchange of India Limited on October 6, 2026, pursuant to Regulation 30 of the SEBI Listing Regulations. This communication serves as an update to the earlier disclosure dated October 1, 2026, which had outlined the initial schedule.

Meeting Schedule Details

The following table details the planned events as disclosed by the company:

The company noted that all other details as disclosed in the previous communication remain unchanged. Changes to the schedule may still occur due to exigencies on the part of participants, hosts, or the company itself.

Disclosure Guidelines

India Glycols emphasized that all discussions during these interactions will be based strictly on publicly available information. The company explicitly stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the sessions. This ensures compliance with regulatory standards regarding fair disclosure to all market participants.

The intimation letter was signed by Ankur Jain, Head (Legal) & Company Secretary. The document is also hosted on the company's official website for public access.